黏多醣症治療市場規模、佔有率和成長分析：按黏多醣貯積症類型、療法、通路、最終用戶和地區分類－2026-2033年產業預測

2024 年全球黏多醣症治療市場價值為 25.2 億美元，預計到 2025 年將成長至 27.5 億美元，到 2033 年將成長至 55.2 億美元，在預測期（2026-2033 年）內複合年成長率為 9.12%。

受罕見遺傳疾病盛行率上升以及酵素替代療法和基因療法進展的推動，全球黏多醣症治療市場正經歷顯著成長。新生兒篩檢計畫在各地區的普及使得早期診斷成為可能，從而增加了對超越單純症狀管理的有效治療的需求。諸如Glucosidaseα等創新療法的推出引起了監管機構的關注，加速了研發投入，並將該市場發展成為一個數十億美元的產業。此外，精準醫療正在推動更個人化的治療，降低治療中斷率，並增強保險公司對報銷的信心。向新興經濟體的市場擴張，以及策略合作和創新定價策略，正在進一步鞏固這一關鍵治療領域持續成長的基礎。

全球黏多醣症治療市場的成長要素

全球對黏多醣症的認知不斷提高，導致確診病例增加，迫使醫療機構和保險公司優先考慮治療。隨著臨床醫生對與該疾病相關的整形外科症狀了解的加深，越來越多的患者被轉診至專科治療中心，這反過來又增加了對已通過核准療法的需求，並刺激了對新藥研發的投資。此外，臨床關注度的提高促進了配套服務的建立，豐富了整個市場生態系統，並推動了各個地區的永續成長。因此，患者數量的增加和治療效果的改善增強了相關人員的信心，並為永續的長期市場擴張創造了機會。

全球黏多醣症治療市場的阻礙因素

酵素替代療法和基因療法的高昂費用給私人和公共保險預算都帶來了巨大的財政挑戰。這些費用使臨床醫生開處方流程複雜化，並阻礙了患者獲得這些必需藥物，通常導致醫保覆蓋範圍有限、保險公司強制要求事先核准以及報銷選擇不足。此外，隨著這些療法逐步滲透市場，製造商被迫投入大量資源進行價格談判和患者支持措施，阻礙了市場的整體成長。因此，醫療保健相關人員持續面臨的財政壓力正在影響政策決策，因為衛生部門需要在成本和患者可獲得的替代療法之間進行權衡。

黏多醣症治療的全球市場趨勢

受基因治療和基因編輯技術（例如 CRISPR）的顯著進步驅動，全球黏多醣症治療市場正經歷變革性的變化。這種改變催生了不同於傳統療法的創新療法，從而形成了新的競爭格局。各公司正在改進載體技術，以維持酶的長期表達，同時最大限度地減少免疫反應。同時，合作臨床計畫正著重於早期療育策略，旨在保護新生兒和兒童的器官功能。這些科學突破正在催生靈活的監管流程，從而促進新療法的快速核准，預示著治療方法模式轉移，超越傳統的酵素替代療法。

目錄

介紹

• 調查目的
• 市場定義和範圍

調查方法

• 研究過程
• 二級資料和一級資料的方法
• 市場規模估算方法

執行摘要

• 全球市場展望
• 市場主要亮點
• 細分市場概覽
• 競爭環境概述

市場動態及展望

• 總體經濟指標
• 促進者和機會
• 抑制因素和挑戰
• 供給面趨勢
• 需求面趨勢
• 波特的分析和影響

關鍵市場分析

• 關鍵成功因素
• 影響市場的因素
• 主要投資機會
• 生態系測繪
• 2025年市場魅力指數
• PESTLE分析
• 監理情勢

全球黏多醣症治療市場規模：以黏多醣貯積症類型分類

• MPS I（哈勒型/謝伊型）
• MPS II（韓特氏症）
• MPS IVA（莫爾西奧症候群）
• MPS VI（馬羅托雷-拉米型）

全球黏多醣症治療市場規模：依治療方法分類

• 酵素替代療法（ERT）
• 造血幹細胞移植
• 基因療法（開發平臺）

全球黏多醣症治療市場規模：依通路分類

• 醫院藥房
• 專科藥房

全球黏多醣症治療市場規模：依最終用戶分類

• 遺傳疾病中心
• 醫院

全球黏多醣症治療市場規模：依地區分類

• 北美洲
  • 美國
  • 加拿大
• 歐洲
  • 德國
  • 西班牙
  • 法國
  • 英國
  • 義大利
  • 其他歐洲國家
• 亞太地區
  • 中國
  • 印度
  • 日本
  • 韓國
  • 其他亞太國家
• 拉丁美洲
  • 墨西哥
  • 巴西
  • 其他拉丁美洲國家
• 中東和非洲
  • 海灣合作理事會國家
  • 南非
  • 其他中東和非洲國家

競爭資訊

• 前五大公司對比
• 主要公司2025年的市場定位
• 主要市場公司採取的策略
• 近期市場趨勢
• 企業市場占有率分析，2025 年
• 主要公司的完整公司簡介
  • 公司詳情
  • 產品系列分析
  • 按細分市場進行企業市佔率分析
  • 銷售收入年比比較（2023-2025 年）

主要公司簡介

• BioMarin Pharmaceutical（Aldurazyme, Vimizim, Naglazyme）
• Takeda Pharmaceutical（Elaprase）
• Sanofi Genzyme
• Ultragenyx Pharmaceutical
• JCR Pharmaceuticals
• Chiesi Farmaceutici
• Inventiva SA
• RegenxBio Inc.
• Allievex Corporation
• Denali Therapeutics
• Homology Medicines
• REGENXBIO Inc.
• Lysogene SA
• Orchard Therapeutics
• Sangamo Therapeutics
• Sio Gene Therapies
• Avrobio Inc.
• Spark Therapeutics（Roche）
• 4D Molecular Therapeutics
• Passage Bio

結論與建議

Global Mucopolysaccharidosis Treatment Market size was valued at USD 2.52 Billion in 2024 and is poised to grow from USD 2.75 Billion in 2025 to USD 5.52 Billion by 2033, growing at a CAGR of 9.12% during the forecast period (2026-2033).

The global mucopolysaccharidosis treatment market is experiencing significant growth, driven by the rising prevalence of rare genetic disorders and advancements in enzyme replacement and gene therapies. Increased availability of newborn screening programs across various regions has enabled earlier diagnosis, amplifying the demand for effective treatments beyond mere symptom management. The introduction of innovative therapies, like alglucosidase alfa, has led to heightened regulatory focus and accelerated R&D investments, transforming the market into a multi-billion-dollar sector. Additionally, precision medicine is enhancing treatment personalization, reducing abandonment rates, and boosting payer confidence in reimbursement. The market's expansion into emerging economies, coupled with strategic partnerships and innovative pricing approaches, further establishes a robust foundation for ongoing growth in this vital therapeutic area.

Top-down and bottom-up approaches were used to estimate and validate the size of the Global Mucopolysaccharidosis Treatment market and to estimate the size of various other dependent submarkets. The research methodology used to estimate the market size includes the following details: The key players in the market were identified through secondary research, and their market shares in the respective regions were determined through primary and secondary research. This entire procedure includes the study of the annual and financial reports of the top market players and extensive interviews for key insights from industry leaders such as CEOs, VPs, directors, and marketing executives. All percentage shares split, and breakdowns were determined using secondary sources and verified through Primary sources. All possible parameters that affect the markets covered in this research study have been accounted for, viewed in extensive detail, verified through primary research, and analyzed to get the final quantitative and qualitative data.

Global Mucopolysaccharidosis Treatment Market Segments Analysis

Global mucopolysaccharidosis treatment market is segmented by mps type, treatment, distribution, end-user and region. Based on mps type, the market is segmented into MPS I (Hurler/Scheie), MPS II (Hunter Syndrome), MPS IVA (Morquio Syndrome) and MPS VI (Maroteaux-Lamy). Based on treatment, the market is segmented into Enzyme Replacement Therapy (ERT), Hematopoietic Stem Cell Transplant and Gene Therapy (Pipeline). Based on distribution, the market is segmented into Hospital Pharmacies and Specialty Pharmacies. Based on end-user, the market is segmented into Genetic Disease Centers and Hospitals. Based on region, the market is segmented into North America, Europe, Asia Pacific, Latin America and Middle East & Africa.

Driver of the Global Mucopolysaccharidosis Treatment Market

The rising global recognition of mucopolysaccharidoses is leading to an increasing number of diagnosed patients, compelling healthcare providers and payers to prioritize therapeutic options. As clinicians gain a deeper understanding of the orthopedic manifestations associated with these disorders, more patients are being directed to specialized treatment centers, thereby boosting the demand for approved therapies and attracting investment in emerging drug developments. Furthermore, heightened clinical interest facilitates the creation of supportive services, which enriches the overall market ecosystem and fosters sustained growth across various regions. Consequently, the growing patient population and successful treatment outcomes are enhancing stakeholder confidence and creating opportunities for sustainable long-term market expansion.

Restraints in the Global Mucopolysaccharidosis Treatment Market

The high cost associated with enzyme replacement and gene-based therapies imposes significant financial challenges on both private and public insurance budgets. Such expenses complicate the prescribing process for clinicians and create barriers for patients' access to these essential medications, often resulting in formulary restrictions, mandatory prior approval from insurance providers, and inadequate reimbursement options. Furthermore, the gradual penetration of these therapies into the market forces manufacturers to invest considerable resources in pricing negotiations and patient-assistance initiatives, hindering overall market growth. Consequently, the persistent financial pressure on healthcare stakeholders influences policy decisions as health authorities weigh costs against the availability of alternative treatments for patients.

Market Trends of the Global Mucopolysaccharidosis Treatment Market

The Global Mucopolysaccharidosis Treatment market is undergoing a transformative shift enabled by significant advancements in gene therapy and gene editing technologies such as CRISPR. This evolution is leading to the development of innovative treatments that diverge from conventional options, fostering a new competitive landscape. Companies are enhancing vector technology to ensure prolonged enzyme expression with minimal immune response, while collaborative clinical programs emphasize early intervention strategies aimed at preserving organ function in neonates and children. These scientific breakthroughs are creating adaptive regulatory pathways that facilitate the accelerated approval of novel therapies, signaling a paradigm shift in treatment approaches beyond traditional enzyme replacement therapies.

Table of Contents

Introduction

• Objectives of the Study
• Market Definition & Scope

Research Methodology

• Research Process
• Secondary & Primary Data Methods
• Market Size Estimation Methods

Executive Summary

• Global Market Outlook
• Key Market Highlights
• Segmental Overview
• Competition Overview

Market Dynamics & Outlook

• Macro-Economic Indicators
• Drivers & Opportunities
• Restraints & Challenges
• Supply Side Trends
• Demand Side Trends
• Porters Analysis & Impact
  • Competitive Rivalry
  • Threat of Substitute
  • Bargaining Power of Buyers
  • Threat of New Entrants
  • Bargaining Power of Suppliers

Key Market Insights

• Key Success Factors
• Market Impacting Factors
• Top Investment Pockets
• Ecosystem Mapping
• Market Attractiveness Index 2025
• PESTEL Analysis
• Regulatory Landscape

Global Mucopolysaccharidosis Treatment Market Size by MPS Type & CAGR (2026-2033)

• Market Overview
• MPS I (Hurler/Scheie)
• MPS II (Hunter Syndrome)
• MPS IVA (Morquio Syndrome)
• MPS VI (Maroteaux-Lamy)

Global Mucopolysaccharidosis Treatment Market Size by Treatment & CAGR (2026-2033)

• Market Overview
• Enzyme Replacement Therapy (ERT)
• Hematopoietic Stem Cell Transplant
• Gene Therapy (Pipeline)

Global Mucopolysaccharidosis Treatment Market Size by Distribution & CAGR (2026-2033)

• Market Overview
• Hospital Pharmacies
• Specialty Pharmacies

Global Mucopolysaccharidosis Treatment Market Size by End-User & CAGR (2026-2033)

• Market Overview
• Genetic Disease Centers
• Hospitals

Global Mucopolysaccharidosis Treatment Market Size & CAGR (2026-2033)

• North America (MPS Type, Treatment, Distribution, End-User)
  • US
  • Canada
• Europe (MPS Type, Treatment, Distribution, End-User)
  • Germany
  • Spain
  • France
  • UK
  • Italy
  • Rest of Europe
• Asia Pacific (MPS Type, Treatment, Distribution, End-User)
  • China
  • India
  • Japan
  • South Korea
  • Rest of Asia-Pacific
• Latin America (MPS Type, Treatment, Distribution, End-User)
  • Mexico
  • Brazil
  • Rest of Latin America
• Middle East & Africa (MPS Type, Treatment, Distribution, End-User)
  • GCC Countries
  • South Africa
  • Rest of Middle East & Africa

Competitive Intelligence

• Top 5 Player Comparison
• Market Positioning of Key Players, 2025
• Strategies Adopted by Key Market Players
• Recent Developments in the Market
• Company Market Share Analysis, 2025
• Company Profiles of All Key Players
  • Company Details
  • Product Portfolio Analysis
  • Company's Segmental Share Analysis
  • Revenue Y-O-Y Comparison (2023-2025)

Key Company Profiles

• BioMarin Pharmaceutical (Aldurazyme, Vimizim, Naglazyme)
  • Company Overview
  • Business Segment Overview
  • Financial Updates
  • Key Developments
• Takeda Pharmaceutical (Elaprase)
  • Company Overview
  • Business Segment Overview
  • Financial Updates
  • Key Developments
• Sanofi Genzyme
  • Company Overview
  • Business Segment Overview
  • Financial Updates
  • Key Developments
• Ultragenyx Pharmaceutical
  • Company Overview
  • Business Segment Overview
  • Financial Updates
  • Key Developments
• JCR Pharmaceuticals
  • Company Overview
  • Business Segment Overview
  • Financial Updates
  • Key Developments
• Chiesi Farmaceutici
  • Company Overview
  • Business Segment Overview
  • Financial Updates
  • Key Developments
• Inventiva SA
  • Company Overview
  • Business Segment Overview
  • Financial Updates
  • Key Developments
• RegenxBio Inc.
  • Company Overview
  • Business Segment Overview
  • Financial Updates
  • Key Developments
• Allievex Corporation
  • Company Overview
  • Business Segment Overview
  • Financial Updates
  • Key Developments
• Denali Therapeutics
  • Company Overview
  • Business Segment Overview
  • Financial Updates
  • Key Developments
• Homology Medicines
  • Company Overview
  • Business Segment Overview
  • Financial Updates
  • Key Developments
• REGENXBIO Inc.
  • Company Overview
  • Business Segment Overview
  • Financial Updates
  • Key Developments
• Lysogene SA
  • Company Overview
  • Business Segment Overview
  • Financial Updates
  • Key Developments
• Orchard Therapeutics
  • Company Overview
  • Business Segment Overview
  • Financial Updates
  • Key Developments
• Sangamo Therapeutics
  • Company Overview
  • Business Segment Overview
  • Financial Updates
  • Key Developments
• Sio Gene Therapies
  • Company Overview
  • Business Segment Overview
  • Financial Updates
  • Key Developments
• Avrobio Inc.
  • Company Overview
  • Business Segment Overview
  • Financial Updates
  • Key Developments
• Spark Therapeutics (Roche)
  • Company Overview
  • Business Segment Overview
  • Financial Updates
  • Key Developments
• 4D Molecular Therapeutics
  • Company Overview
  • Business Segment Overview
  • Financial Updates
  • Key Developments
• Passage Bio
  • Company Overview
  • Business Segment Overview
  • Financial Updates
  • Key Developments

Conclusion & Recommendations